12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aclidinium bromide regulatory update

FDA's Pulmonary-Allergy Drugs Advisory Committee voted 12-2 that the benefit-risk profile for aclidinium bromide from Forest supports approval to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD). The vote follows briefing documents released earlier...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >